Relapsing-remitting multiple sclerosis: What is the potential for combination therapy?

被引：0
作者：
Mäurer M. [1 ]
Rieckmann P. [1 ,2 ]
机构：
[1] Clin. Res. U. Multiple Sclerosis/N., Department of Neurology, Bayerische Julius-Maximilians Univ., Würzburg
[2] Klin. Forschungsgruppe Multiple S., Neurologische Klin./Poliklin. B., 97080 Würzburg
来源：
BioDrugs | 2000年 / 13卷 / 3期
关键词：
Multiple Sclerosis; Major Histocompatibility Complex; Experimental Autoimmune Encephalomyelitis; Myelin Basic Protein; Mitoxantrone;
D O I：
10.2165/00063030-200013030-00001
中图分类号：
学科分类号：
摘要：
Multiple sclerosis is now a treatable disease and several immunomodulating therapies exist, but their clinical efficacy is moderate and treatment failure during the course of the disease is an increasing problem. As agents with different targets are available, the question was raised whether combination of these therapies would: (i) be safe; (ii) result in reduction of adverse effects; and (iii) provide synergistic benefit by additive or complementary modes of action. The areas under clinical investigation are general immunosuppression as well as more targeted approaches that interfere with antigen presentation, immune cell transmigration, release of myelinotoxic factors or even axonal damage. Combination of these immunomodulatory drugs seems to be rational and promising. Nevertheless, combination therapies need to be studied in carefully designed clinical trials in selected patient populations in order to demonstrate additive or synergistic effects. This article will summarize current drug combination strategies in relapsing-remitting multiple sclerosis and provide an overview of the initial clinical trials.
引用
收藏
页码：149 / 158
页数：9
相关论文
共 70 条
  • [1] Oliveri R.L., Valentino P., Russo C., Et al., Randomized trial comparing two different high doses of methylprednisolone in MS, Neurology, 50, pp. 1833-1836, (1998)
  • [2] Edan G., Miller D., Clanet M., Et al., Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomized multicenter study of active disease using MRI and clinical criteria, J Neurol Neursurg Psychiatry, 62, pp. 112-118, (1997)
  • [3] Jacobs L.D., Cookfair D.L., Rudick R.A., Intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis, Ann Neurol, 39, pp. 285-294, (1996)
  • [4] Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis, Lancet, 352, pp. 1498-1504, (1998)
  • [5] Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43, pp. 655-661, (1993)
  • [6] Rudick R.A., Fisher E., Lee J.C., Et al., Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS, Neurology, 53, pp. 1698-1704, (1999)
  • [7] Johnson K.P., Brooks B.R., Cohen J.A., Et al., Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial, Neurology, 45, pp. 1268-1276, (1995)
  • [8] Johnson K.P., Brooks B.R., Cohen J.A., Et al., Extended use of glatiramer acetate (copaxone) is well tolerated and maintains its clinical effects on multiple sclerosis relapse rate and degree of disability, Neurology, 50, pp. 701-708, (1998)
  • [9] Comi G., Filippi M., The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): A multi-center, randomised, double-blind, placebo-controlled study extended by open label treatment, Neurology, 52, SUPPL. 2, (1999)
  • [10] Goodkin D.E., Bailly R.C., Teetzen M.I., Et al., The efficacy of azathioprine in relapsing remitting multiple sclerosis, Neurology, 41, pp. 20-25, (1991)
1234567